Cite
HARVARD Citation
Moerman, R. et al. (2014). EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Annals of the rheumatic diseases. 73 (2), pp. 472-474. [Online].